How to dose CagriSema

CagriSema dosing: the essentials

• CagriSema is dosed as a weekly subcutaneous injection at a fixed 1:1 (mg:mg) ratio, and it is stepped up in increments every 4 weeks from 0.25 mg/0.25 mg up to a maintenance dose of 2.4 mg/2.4 mg
• The titration is slower than it is with semaglutide monotherapy, which reflects the additive gastrointestinal tolerability burden of two long-half-life peptides that accumulate in parallel
• The phase 2 trial by Frias et al. (Lancet, 2023) confirmed that nausea and vomiting were concentrated in the escalation phase and were managed by delaying the move to the next step rather than by reducing the dose on a permanent basis
• As of 2026, CagriSema is an investigational product with no marketing authorisation
• Dose pauses and the protocols for missed injections follow a structured decision tree that is based on tolerability and on the pharmacokinetic half-life (~7 days for both components)

---

CagriSema (cagrilintide + semaglutide) is dosed as a weekly subcutaneous injection at a fixed 1:1 (mg:mg) ratio, and it is stepped up in 4-week increments from 0.25 mg/0.25 mg to a maintenance dose of 2.4 mg/2.4 mg [3][8]. The titration is deliberately slower than it is with semaglutide monotherapy, because the amylin analogue cagrilintide brings its own gastrointestinal (GI) tolerability burden with it. The phase 2 trial by Frias et al. (Lancet, 2023) confirmed that most cases of nausea and vomiting were concentrated in the escalation phase and were managed by delaying the next move up the schedule rather than by reducing the dose on a permanent basis [3]. That slower pace is not arbitrary: it follows directly from the additive gastrointestinal signalling of two long-half-life peptides that accumulate in parallel.

This article covers the standard CagriSema escalation schedule, explains why its titration differs from that of semaglutide on its own, and describes how dose pauses and missed injections are handled in the published protocols.

CagriSema is not part of Body Pharm's catalogue for Spain: this guide treats it purely as a reference compound.

Standard escalation schedule (research reference)

As of 2026, CagriSema is an investigational product with no marketing authorisation [5][7].

What CagriSema is: the mechanism in brief

CagriSema is a fixed-ratio 1:1 (mg:mg) co-formulation of cagrilintide, a long-acting amylin analogue, and semaglutide, an agonist of the GLP-1 (glucagon-like peptide-1) receptor, given as a single subcutaneous injection once a week [8]. The two peptides act through pathways that are distinct from one another but complementary, and that is why the titration protocol cannot simply copy the escalation schedule across from the Semaglutide dosing guide.

Cagrilintide mimics pancreatic amylin: it slows gastric emptying, suppresses postprandial glucagon and acts on the area postrema circuits in the hindbrain to reduce food intake. Semaglutide, for its part, activates GLP-1 receptors to enhance glucose-dependent insulin secretion and to produce central appetite suppression through hypothalamic and brainstem signalling. The two effects are additive rather than redundant, so the gastrointestinal tolerability burden stacks up while the two are being titrated together, and the escalation pace therefore has to be more conservative than it is in GLP-1 monotherapy. For the wider mechanistic context against triple agonists and dual incretin agents, see the Retatrutide vs semaglutide vs tirzepatide comparison.

Both of the components have an elimination half-life of around 7 days (cagrilintide ~7–8 days according to phase 1 pharmacokinetic (PK) work [1]; semaglutide ~7 days [6]). That shared pharmacokinetic profile is what makes synchronised once-weekly administration in a single injection possible.

Regulatory status

As of 2026, CagriSema has no marketing authorisation and is in phase 3 development by Novo Nordisk within the REDEFINE programme (REDEFINE 1, NCT05567796) [5]. As an investigational product, it is not intended for therapeutic use in humans.

Why CagriSema needs a slower titration than semaglutide on its own

CagriSema uses the same four-week intervals as semaglutide, but the tolerability burden at each step is higher, because two peptides with long half-lives are accumulating in parallel. Both cagrilintide (t½ ~7–8 days [1]) and semaglutide (t½ ~7 days [6]) approach steady state over the course of roughly four to five half-lives. During each four-week hold, the plasma concentrations of both agents are still climbing towards their plateau before the next escalation takes place.

The problem, mechanistically, is additive gastrointestinal signalling. Cagrilintide slows gastric emptying through amylin receptor activity in the area postrema. Semaglutide, independently, delays gastric emptying and suppresses appetite through GLP-1 receptor signalling. Combining the two of them at every step produces a nausea and vomiting signal that builds up faster than it does with GLP-1 monotherapy at an equivalent dose. Both REDEFINE 1 (NCT05567796) and the phase 2 trial by Frias et al. (2023) reported that gastrointestinal adverse events were concentrated in the escalation phase and were the main reason for pauses in dosing. Management relied on delaying the move to the next step rather than on any permanent reduction in dose [3][8].

Step-by-step comparison with semaglutide monotherapy

The escalation pace of the reference protocol matches, number for number, the standard set out in the Semaglutide dosing guide, but the tolerability burden at each step is not equivalent between the two.

The four-week hold is not negotiable. Shortening it, even when steps 1 and 2 appear to be well tolerated, means moving up to the next dose before cagrilintide has had the chance to reach the plasma concentration that drives its tolerability signal. For the broader, cross-class context on what happens when additive mechanisms are combined, see the Retatrutide vs semaglutide vs tirzepatide comparison.

CagriSema titration schedule: the full protocol table

The complete CagriSema titration protocol runs through five fixed phases over 16 weeks, with maintenance from week 17 onwards at 2.4 mg of cagrilintide + 2.4 mg of semaglutide once a week in a fixed-ratio 1:1 co-formulation [3][8]. Because the co-formulation carries both of the peptides in a single subcutaneous injection, there is no mixing to do and no sequential dosing needed at any of the steps.

The 2.4 mg figure refers to each of the two components, not to the total mass. At maintenance, a single weekly injection contains 2.4 mg of cagrilintide plus 2.4 mg of semaglutide [3].

Continuity of supply during the titration

Keeping to the same supply throughout the entire 16-week escalation avoids introducing variability in handling halfway through the titration. The escalation pace described here matches the schedule that was used in REDEFINE 1 (NCT05567796) and is consistent with the four-week step design of the phase 2 protocol of Frias et al. (2023) [3][5].

Research notice: as of 2026, CagriSema (cagrilintide + semaglutide) has no marketing authorisation and remains a phase 3 investigational product [7]. The schedule above serves solely as a reference for analytical and research purposes, and not as clinical guidance.

For the comparison with a single peptide on its own, see the Semaglutide dosing guide; for the multi-mechanism context against the triple agonists, see the Retatrutide vs semaglutide vs tirzepatide comparison.

Reported parameters for subcutaneous administration

CagriSema is given as a single weekly subcutaneous injection drawn from the fixed-ratio co-formulation. The handling described in the literature for research purposes matches semaglutide injection practice, with closer attention paid to rotating the injection site, because two peptides with long half-lives are being deposited in the same place every week.

The protocols call for taking the product out of 2–8 °C storage and letting it stand for around 30 minutes at room temperature before the injection is given. According to reports, cold peptide solutions sting more on administration and can trigger transient site reactions that confound the tolerability assessment during the titration.

Site selection and rotation

Three suitable subcutaneous sites are described: the abdomen (keeping a 5 cm radius around the navel clear), the anterolateral upper thigh and the back of the upper arm. The protocols described rotate between sites from one week to the next, rather than dosing again and again into the same quadrant. With peptides that are given once a week, depositing the dose repeatedly into the same fat pad is the classic trigger for lipohypertrophy, which alters the absorption kinetics and can blunt steady-state plasma concentrations.

Needle angle and skin fold

The technique described uses a 4–6 mm needle at 90° for abdominal injection in subjects with sufficient subcutaneous depth, or a pinched skin fold at a 45° angle in the thigh and upper arm, where the fat layer is thinner. The protocols describe injecting, holding the needle in place for 6 seconds so that the full dose is delivered, and then withdrawing it and discarding the needle in a puncture-resistant sharps container.

A consistent dosing day

The protocols described fix the injection on the same day of the week (every Monday, for example). Both cagrilintide and semaglutide have elimination half-lives of ~1 week, so synchronised weekly dosing maintains an overlapping steady-state exposure to both components [1][6]. Shifting the dosing day by more than 48 hours in the middle of the titration upsets the additive pharmacokinetic profile on which the REDEFINE 1 schedule is built [5].

For the injection technique that maps directly onto the GLP-1 component, see the Semaglutide dosing guide.

Decision tree for dose pauses: when should escalation stop?

The protocols described hold the current dose for another 4 weeks whenever moderate gastrointestinal symptoms are present at the point where the escalation was planned, and they step down one level if the symptoms turn out to be severe. CagriSema's dual receptor pharmacology (amylin from cagrilintide plus GLP-1 from semaglutide) means that the additivity of the gastrointestinal signal is greater than it is in semaglutide monotherapy. The standard 4-week escalation pace used in REDEFINE 1 should be treated as the maximum speed at which to proceed, not as the norm [5][8].

The phase 2 protocol of Frias et al. (2023) expressly allowed the move to the next step to be delayed and dosing to be interrupted temporarily in the face of intolerable gastrointestinal events. Neither routine prophylactic antiemetics nor permanent reductions below the maintenance dose formed part of the design [3]. REDEFINE 1 followed the same logic: dose reductions were permitted, but skipping escalation steps was not [5][8].

Decision table

Why skipping steps is not supported

Skipping a step (going from 0.5 mg straight to 1.7 mg while omitting 1.0 mg, for instance) is not provided for in either the REDEFINE 1 protocol or the phase 2 protocol of Frias et al. (2023), and it has no published pharmacokinetic or tolerability data behind it [5][3]. Each 4-week interval gives both peptides the time to reach steady state at the new level of exposure before the next increment is made. Both of them have half-lives of ~1 week [1][6]. Shortening that window stacks the rising trough concentrations of cagrilintide and of semaglutide on top of each other at the same time, which is precisely what the stepped increase is meant to avoid.

To see how this conservative pace differs from the way a single peptide is escalated, the Semaglutide dosing guide describes the monotherapy schedule, and the Retatrutide vs semaglutide vs tirzepatide comparison places CagriSema within the broader multi-mechanism class.

Missed-dose protocol: what to do

If a dose of CagriSema is missed, the rule derived from the authorised semaglutide products (Ozempic, Wegovy) is to give the missed dose within the 5 days following the scheduled day, or to skip it entirely if 5 days or more have gone by [6]. As of 2026, CagriSema has no marketing authorisation [7], so this guidance is borrowed from the closest authorised analogue and it applies only in a research context.

Because both cagrilintide and semaglutide have ~7-day half-lives [1][6], missing a single week produces only a moderate drop in the trough concentration, not a complete washout. Tolerability at the step that has already been established is usually preserved, so continuing at the current titration step (rather than stepping back) is consistent with the pharmacokinetic rationale. Research protocols typically keep a log of the date, the time, the dose and the injection site throughout the titration, which is the simplest safeguard there is against accidental double dosing. For the comparison with the handling of missed doses of a single peptide, the Semaglutide dosing guide sets out the monotherapy rule in full.

Storing and handling CagriSema

Unopened CagriSema is stored in the refrigerator at 2–8 °C, protected from direct light, and it is never frozen. Once the pack has been started, the in-use window described is up to 28 days below 30 °C. That limit is taken from the Wegovy summary of product characteristics (SmPC), as the closest authorised semaglutide analogue [6], and it is treated as a conservative ceiling for research purposes, given that there are no CagriSema-specific stability data for the product after opening.

Freezing destroys the higher-order structure of both cagrilintide and semaglutide, and it renders the product unusable even once it has thawed. Any visible cloudiness, or any particles in the solution, are grounds for discarding it. For the analogous storage logic for a single peptide, see the Semaglutide dosing guide; for the broader context across agents, the Retatrutide vs semaglutide vs tirzepatide comparison covers the handling differences within the class.

CagriSema versus semaglutide on its own: why combine them?

CagriSema adds a synthetic amylin analogue (cagrilintide) to semaglutide in order to recruit a second satiety pathway that GLP-1 agonism on its own does not fully cover. In REDEFINE 1, CagriSema 2.4 mg/2.4 mg once a week achieved a mean body-weight reduction of 20.4% at 68 weeks, against 3.0% with placebo [8]. Semaglutide 2.4 mg given as monotherapy achieved a mean reduction of about 14.9% over that same 68-week window in STEP 1 (2021), and that is the benchmark against which the two-peptide approach is compared [6][9].

The mechanistic rationale is additive, not redundant. Cagrilintide, a long-acting amylin analogue with an elimination half-life of 7–8 days, slows gastric emptying and dampens postprandial glucagon secretion at the amylin and calcitonin receptors [1][2]. Semaglutide acts on the GLP-1 receptor in pancreatic β-cells and in the central appetite circuits, with a comparable half-life of ~7 days that allows synchronised weekly dosing in a single co-formulation [6]. The two peptides converge on the same end point, appetite suppression, but they get there through distinct receptor families. That is why the phase 2 trial by Frias et al. (2023) showed efficacy gains over matched semaglutide arms without an entirely new adverse-event signature appearing. The gastrointestinal profile remained the axis that limited the dose [3].

For the broader context on how this two-peptide design compares with triple agonists and with GIP/GLP-1 strategies, the Retatrutide vs semaglutide vs tirzepatide comparison describes the receptor pharmacology differences within the current class of investigational products. As of 2026, CagriSema is an investigational product with no marketing authorisation [5][7].

CagriSema in the research context: regulatory status (2026)

As of 2026, CagriSema is not authorised for therapeutic use and remains a phase 3 investigational product within the REDEFINE programme [5]. It is not an authorised medicine and it is not intended for therapeutic use in humans.

This regulatory position differs from that of the authorised semaglutide products (Ozempic for type 2 diabetes, Wegovy for weight management), which are independent authorised medicines with their own SmPCs and their own dosing schedules. The titration framework in the Semaglutide dosing guide reflects that authorised-medicine context, and it should not be carried over directly to research work that involves CagriSema.

Researchers should work within the legal requirements that apply to them and within their institution's ethical governance for all in vitro and analytical work. For additional receptor pharmacology context within the class of investigational products, the Retatrutide vs semaglutide vs tirzepatide comparison shows where CagriSema's two-peptide design sits in relation to triple-agonist and GIP/GLP-1 strategies.

Frequently Asked Questions

Frequently asked questions on CagriSema dosing, answered solely with the research context in mind. As of 2026, CagriSema is an investigational product with no marketing authorisation [5][7].

What is the starting dose of CagriSema?

The starting dose used in the CagriSema phase 2 and phase 3 protocols is 0.25 mg of cagrilintide plus 0.25 mg of semaglutide once a week, given as a fixed 1:1 (mg:mg) co-formulation [3][5]. It matches the starting step for semaglutide, but it pairs it, from the very first week, with an equivalent dose of the amylin analogue.

How long does the full titration take?

The full titration up to the 2.4 mg / 2.4 mg maintenance dose takes around 16–20 weeks with a fixed 4-week escalation at each step (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) [3][5]. That matches the escalation pace used in both the phase 2 trial by Frias et al. (2023) and REDEFINE 1.

Can the titration be sped up?

No published CagriSema study supports an accelerated escalation. The phase 2 trial by Frias et al. (2023) fixes a 4-week interval; the only deviation the protocol provides for is delaying the move to the next step when gastrointestinal symptoms are present [3]. Shortening the escalation removes the margin of tolerability on which the whole two-peptide design depends. See the Semaglutide dosing guide for the comparison with the authorised monotherapy.

What is the maintenance dose of CagriSema?

The target maintenance dose is 2.4 mg of cagrilintide plus 2.4 mg of semaglutide once a week, given in a single subcutaneous injection [5]. Both peptides have elimination half-lives of ~7 days, which is what makes synchronised weekly dosing possible [1][6].

Can CagriSema be combined with other investigational peptides?

The published study data do not support combination work with other agents belonging to the incretin class. For the comparative receptor pharmacology context within the class of investigational products, see the Retatrutide vs semaglutide vs tirzepatide comparison.

Is CagriSema available as a research peptide?

CagriSema is an investigational product in phase 3 development. It is not an authorised medicine and it is not intended for therapeutic use in humans [5][7].

Next steps

Anyone planning protocols with CagriSema should secure institutional ethical approval and ensure compliance with the applicable regulatory requirements before starting any work. See the Semaglutide dosing guide for comparisons with a single peptide, and the Retatrutide vs semaglutide vs tirzepatide comparison for the wider multi-mechanism context.

Sources

1. Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021. pubmed.ncbi.nlm.nih.gov/33894838
2. Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021. pubmed.ncbi.nlm.nih.gov/34798060
3. Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023. pubmed.ncbi.nlm.nih.gov/37364590
4. Verma S, et al. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 (secondary analysis of the phase 3 programme). Hypertension. 2026. pubmed.ncbi.nlm.nih.gov/41328546
5. ClinicalTrials.gov, registry record for the REDEFINE 1 trial (NCT05567796): once-weekly CagriSema 2.4 mg/2.4 mg in adults with overweight or obesity, phase 3, 68 weeks; accessed October 2026. clinicaltrials.gov/study/NCT05567796
6. EMA, EPAR and summary of product characteristics (SmPC) for Wegovy (semaglutide 2.4 mg): posology, escalation, missed doses and storage. ema.europa.eu
7. EMA, list of medicines for human use authorised in the EU (EPAR). ema.europa.eu — accessed in October 2026 for the compound's regulatory status.
8. Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635-647. pubmed.ncbi.nlm.nih.gov/40544433
9. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov/33567185
10. Davies MJ, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med. 2025;393(7):648-659. pubmed.ncbi.nlm.nih.gov/40544432